Corbus Pharmaceuticals (CRBP) announced the European Society for Medical Oncology, ESMO, Congress 2025 abstract for its Phase 1/2 clinical study has been released. Updated data will be presented as a poster during ESMO. The abstract describes safety data for 70 participants from an April 2025 data cut. The poster will present updated data from a September 1st, 2025 data cut on 167 enrolled participants of which 122 participants were evaluable for efficacy with either head and neck squamous cell carcinoma, cervical, metastatic urothelial tumors,or other tumor types enrolled during dose escalation. The poster titled, “Phase 1/2 study of the next-generation Nectin-4-targeting antibody-drug conjugate CRB-701 in patients with urothelial and non-urothelial solid tumours” by Perez et al, will be presented on Sunday, October 19.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Optimistic Buy Rating for Corbus Pharmaceuticals Ahead of Promising CRB-701 Trial Results
- Why Are Cannabis Stocks Up Today?
- Corbus Pharmaceuticals’ CRB-701: A Promising Investment with FDA Fast Track and ESMO 2025 Insights
- Corbus Pharmaceuticals Receives FDA Fast Track for CRB-701
- Corbus Pharmaceuticals receives Fast Track designation for CRB-701